Rivastigmine
- Generic Name
- Rivastigmine
- Brand Names
- Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N2O2
- CAS Number
- 123441-03-2
- Unique Ingredient Identifier
- PKI06M3IW0
- Background
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
- Indication
For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
- Associated Conditions
- Dementia With Lewy Body Disease, Mild Dementia due to Parkinson's disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia, Moderate Dementia due to Parkinson's disease
- Associated Therapies
- -
Rivastigmine Capsules in Patients With Probable Vascular Dementia
- Conditions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 521
- Registration Number
- NCT00130338
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
- Conditions
- First Posted Date
- 2005-03-01
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00104442
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Neuromodulation and Language Acquisition (Stage Ib)
- Conditions
- First Posted Date
- 2005-02-04
- Last Posted Date
- 2010-06-24
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 60
- Registration Number
- NCT00102856
- Locations
- 🇩🇪
Dept. of Neurology, University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany
Neuromodulation and Language Acquisition (Project Stage Ia)
- Conditions
- First Posted Date
- 2005-01-27
- Last Posted Date
- 2010-01-27
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 100
- Registration Number
- NCT00102284
- Locations
- 🇩🇪
Dept. of Neurology, University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
- Conditions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 708
- Registration Number
- NCT00099216
Electrophysiologic Measures of Treatment Response in Alzheimer Disease
- Conditions
- First Posted Date
- 2001-07-05
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- US Department of Veterans Affairs
- Registration Number
- NCT00018278
- Locations
- 🇺🇸
Department of Veterans Affairs, San Diego, California, United States
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
- Conditions
- First Posted Date
- 1999-11-01
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Novartis
- Registration Number
- NCT00000174
- Locations
- 🇺🇸
St. Louis University, St. Louis, Missouri, United States
🇺🇸Clinical Studies, Ltd., Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸St. Paul Medical Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.